Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
tirzepatide
Pharma
Lilly touts winning tirzepatide data in prediabetes patients
Lilly on Wednesday laid out full results from its longest completed study of the dual GIP/GLP-1 receptor agonist tirzepatide to date.
Fraiser Kansteiner
Nov 13, 2024 5:01pm
Amid a new MASH market, ‘tremendous change’ is on the horizon
Nov 5, 2024 10:02am
Lilly cuts revenue guidance as momentum stalls for tirzepatide
Oct 30, 2024 9:47am
FDA reviews decision to put Lilly's tirzepatide on shortage list
Oct 14, 2024 11:20am
Minus one of its GLP-1 cash cows, compounding group sues FDA
Oct 8, 2024 10:52am
FDA removes Lilly's Mounjaro and Zepbound from its shortage list
Oct 3, 2024 11:22am
